Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Researchers from University of Helsinki report on findings in breast cancer
February 19th, 2009
According to recent research from Helsinki, Finland, "To estimate the risk for breast cancer in Finnish women using postmenopausal estradiol (E2)-progestogen therapy. All Finnish women over 50 years using E2-progestogen therapy for at least 6 months in 1994-2005 (N=221,551) were identified from the national medical reimbursement register and followed up for breast cancer incidence (n=6,211 cases) through the Finnish Cancer Registry to the end of 2005." "The risk for breast cancer in E2-progestogen therapy users was compared with that in the general population. The standardized incidence ratio for all types of breast cancer was not elevated within the first 3 years of...
Source: Women's Health Weekly (2009-02-19)
|
